Diclofenac Sodium gel for skin lesion treatment from Glenmark Pharmaceuticals has recently been approved by the United States Food and Drug Administration.
"Glenmark Pharmaceuticals Inc USA has been granted final approval by the USFDA for Diclofenac Sodium gel, 3 per cent, the generic version of Solaraze gel, 3 per cent," the company said in a BSE filing.
‘Glenmark Pharmaceuticals receives FDA approval for diclofenac sodium gel.’
"According to IMS Health sales data for the 12-month period ending July 2016, the Solaraze Gel, 3 per cent market achieved annual sales of approximately $297.9 million," it said.
Glenmark's current portfolio consists of 110 products authorised for distribution in the US marketplace and 61 Abbreviated New Drug Applications (ANDAs) are pending for approval with the USFDA.